1,148
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Hydroxocobalamin and extracorporeal membrane oxygenation (ECMO) for severe refractory shock in bupropion and citalopram overdose: a case report

, , &

References

  • Cole JB, Olives TD, Ulici A, et al. Extracorporeal membrane oxygenation for poisonings reported to U.S. Poison centers from 2000 to 2018: an analysis of the National Poison Data System*. Crit Care Med. 2020;48(8):1111–1119.
  • Isbister GK. Risk assessment of drug-induced QT prolongation. Aust Prescr. 2015;38(1):20–24.
  • Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th annual report. Clin Toxicol (Phila)). 2019;57(12):1220–1413.
  • Schindler CW, Gilman JP, Panlilio LV, et al. Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Exp Clin Psychopharmacol. 2011;19(1):1–10.
  • Kara H, Ak A, Bayır A, et al. Seizures after overdoses of bupropion intake. Balkan Med J. 2013;30(2):248–249.
  • Mainie I, McGurk C, McClintock G, et al. Seizures after buproprion overdose. Lancet. 2001;357(9268):1624.
  • Storrow AB. Bupropion overdose and seizure. Am J Emerg Med. 1994;12(2):183–184.
  • Brown KM, Crouch BI. Bupropion overdose: significant toxicity in pediatrics. Clin Pediatr Emerg Med. 2017;18(3):212–217.
  • Kraai EP, Seifert SA. Citalopram overdose: a fatal case. J Med Toxicol. 2015;11(2):232–236.
  • Catalano G, Catalano MC, Epstein MA, et al. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol. 2001;24(3):158–162.
  • Citalopram hydrobromide [package insert]. Aurobindo Pharma Limited; 2019.
  • Tarabar AF, Hoffman RS, Nelson LS. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4(2):101–105.
  • Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila)). 2007;45(4):315–332.
  • Arias HR, Santamaría A, Ali SF. Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223–255.
  • Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395–401.
  • Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011;21(11):769–772.
  • Walter E, McKinlay J, Corbett J, et al. Review of management in cardiotoxic overdose and efficacy of delayed intralipid use. J Intensive Care Soc. 2018;19(1):50–55.
  • American College of Medical Toxicology. ACMT position statement: guidance for the use of intravenous lipid emulsion. J Med Toxicol. 2017;13(1):124–125.
  • Neal JM, Neal EJ, Weinberg GL. American society of regional anesthesia and pain medicine local anesthetic systemic toxicity checklist: 2020 version. Reg Anesth Pain Med. 2021;46(1):81–82.
  • Feih JT, Rinka JRG, Zundel MT. Methylene blue monotherapy compared with combination therapy with hydroxocobalamin for the treatment of refractory vasoplegic syndrome: ARetrospective Cohort Study. J Cardiothorac Vasc Anesth. 2019;33(5):1301–1307.
  • Hosseinian L, Weiner M, Levin MA, et al. Methylene blue: magic bullet for vasoplegia?Anesth Analg. 2016;122(1):194–201.
  • Levy B, Fritz C, Tahon E, et al. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018;22(1):52.
  • Cai Y, Mack A, Ladlie BL, et al. The use of intravenous hydroxocobalamin as a rescue in methylene blue-resistant vasoplegic syndrome in cardiac surgery . Ann Card Anaesth. 2017;20(4):462–464.
  • Baud FJ, Megarbane B, Deye N, et al. Clinical review: aggressive management and extracorporeal support for drug-induced cardiotoxicity. Crit Care. 2007;11(2):207.
  • Weiner L, Mazzeffi MA, Hines EQ, et al. Clinical utility of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) in patients with drug-induced cardiogenic shock: a retrospective study of the Extracorporeal Life Support Organizations’ ECMO case registry. Clin Toxicol (Phil). 2020;58(7):705–710.
  • Eckman PM, Katz JN, El Banayosy A, et al. Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock: an introduction for the busy clinician. Circulation. 2019;140(24):2019–2037. 10
  • Lo Coco V, Lorusso R, Raffa GM, et al. Clinical complications during veno-arterial extracorporeal membrane oxigenation in post-cardiotomy and non post-cardiotomy shock: still the achille’s heel . J Thorac Dis. 2018;10(12):6993–7004.
  • Bisdas T, Beutel G, Warnecke G, et al. Vascular complications in patients undergoing femoral cannulation for extracorporeal membrane oxygenation support. Ann Thorac Surg. 2011;92(2):626–631.
  • Pillai AK, Bhatti Z, Bosserman AJ, et al. Management of vascular complications of extra-corporeal membrane oxygenation. Cardiovasc Diagn Ther. 2018;8(3):372–377.
  • Gupta V, Gupta R, Wander GS. Role of ECMO in life threatening intoxication. The Egypt J Crit Care Med. 2018;6(3):103–109.